The pending patents cover products for diagnosis of cancer and other serious diseases.
Craig Dees, CEO of Provectus, said: “These cases augment our international portfolio of twenty-six issued patents and four pending patents, along with our US patent portfolio of sixteen issued and five pending patents. As important milestones, they demonstrate the scope of our patent activity that spans markets ranging from the developed world to the rapidly developing world.”